Shire PLC (NASDAQ:SHPG) – Research analysts at William Blair cut their Q4 2017 earnings per share (EPS) estimates for Shire PLC in a research note issued on Monday. William Blair analyst T. Lugo now expects that the biopharmaceutical company will post earnings of $3.72 per share for the quarter, down from their previous forecast of $3.76.
Shire PLC (NASDAQ:SHPG) last issued its earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.64 by $0.17. The business had revenue of $3.70 billion during the quarter. Shire PLC had a return on equity of 14.41% and a net margin of 10.95%. The business’s quarterly revenue was up 7.1% on a year-over-year basis. During the same period last year, the business earned $3.17 EPS. WARNING: “Shire PLC to Post Q4 2017 Earnings of $3.72 Per Share, William Blair Forecasts (SHPG)” was published by Community Financial News and is the property of of Community Financial News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.com-unik.info/2017/11/02/shire-plc-to-post-q4-2017-earnings-of-3-72-per-share-william-blair-forecasts-shpg.html.
A number of other equities analysts have also weighed in on SHPG. HSBC Holdings plc raised shares of Shire PLC from a “reduce” rating to a “hold” rating in a research note on Thursday, July 6th. ValuEngine raised shares of Shire PLC from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. Cantor Fitzgerald set a $222.00 target price on shares of Shire PLC and gave the stock a “buy” rating in a research note on Tuesday, July 11th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $245.00 target price on shares of Shire PLC in a research note on Wednesday, July 12th. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $210.00 target price on shares of Shire PLC in a research note on Thursday, July 13th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $211.00.
Several hedge funds have recently modified their holdings of SHPG. Vanguard Group Inc. raised its holdings in shares of Shire PLC by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 1,542,634 shares of the biopharmaceutical company’s stock valued at $268,773,000 after purchasing an additional 13,665 shares during the period. Geode Capital Management LLC raised its holdings in shares of Shire PLC by 14.0% in the 1st quarter. Geode Capital Management LLC now owns 51,062 shares of the biopharmaceutical company’s stock valued at $8,896,000 after purchasing an additional 6,258 shares during the period. BlackRock Inc. raised its holdings in Shire PLC by 4,217.7% in the 1st quarter. BlackRock Inc. now owns 1,433,475 shares of the biopharmaceutical company’s stock valued at $249,755,000 after acquiring an additional 1,400,275 shares during the period. Independent Portfolio Consultants Inc. raised its holdings in Shire PLC by 27.8% in the 2nd quarter. Independent Portfolio Consultants Inc. now owns 1,626 shares of the biopharmaceutical company’s stock valued at $269,000 after acquiring an additional 354 shares during the period. Finally, Capital One National Association raised its holdings in Shire PLC by 3.4% in the 2nd quarter. Capital One National Association now owns 7,982 shares of the biopharmaceutical company’s stock valued at $1,319,000 after acquiring an additional 261 shares during the period. 19.27% of the stock is currently owned by institutional investors.
The company also recently announced a semiannual dividend, which was paid on Friday, October 20th. Stockholders of record on Friday, September 8th were issued a $0.1527 dividend. The ex-dividend date was Thursday, September 7th. This represents a dividend yield of 0.21%. Shire PLC’s payout ratio is 17.23%.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
What are top analysts saying about Shire PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Shire PLC and related companies.